Imalux Corporation Engages Advisor to Explore Strategic Options
Falls River Group sees immediate market opportunity in mesh and pelvic prolapse patients
NAPLES, Fla., Feb. 22, 2013 /PRNewswire/ — Falls River Group LLC announces they have been engaged by Imalux Corporation, manufacturer of the FDA cleared, Niris 1300e imaging system, to pursue strategic relationships for the company in order to increase the widespread use of the system.
A newly developed application for this amazing technology is in the imaging of vaginal mesh used in the repair of pelvic organ prolapse, as reported in the December 14, 2012 issue of OCT News. Earlier this year, the FDA issued a series of safety communications and requirements to manufacturers of vaginal mesh to do three-year follow-up studies on patients with vaginal mesh implants. Imalux believes that by utilizing the Niris 1300e, physicians and manufacturers now have access to a valuable tool for the visualization of implanted vaginal mesh as part of the mandated post-market studies.
The company also believes the Niris technology will ultimately aid physicians in determining the need for hormonal replacement in the treatment of peri and post-menopausal women by using measurements of the vaginal epithelium. Niris 1300e has been shown to be more accurate, less invasive, and generate more consistent results compared to other imaging technologies such as ultrasound in applications where Niris can be used to evaluate the rate of thinning of the vaginal wall as a determinant for hormone replacement therapy.
ABOUT FALLS RIVER GROUP, LLC
Falls River Group, LLC (FRG) is a Global Merger and Acquisition Advisor based in Naples, Florida. FRG, a member of IMAP (International Merger and Acquisition Partners), has successfully completed over 400 transactions with a combined enterprise value of several billion dollars. IMAP is a global partnership of leading M&A and corporate finance firms formed in 1973. IMAP is the world’s most experienced middle-market M&A partnership, providing real-world solutions for M&A through the collaboration of more than 450 experienced transaction advisors and analysts working seamlessly across borders from offices located in 40 countries, globally ranked 3(rd) in number of closed transactions under $500 million dollars.
ABOUT IMALUX® AND THE NIRIS® IMAGING SYSTEM
Imalux Corporation, based in Cleveland, Ohio, is a leader in the development of site of care imaging systems utilizing harmless, near-infrared light. The Imalux technology platform, sold under the Niris® registered trademark, is based on its proprietary and patented application of Optical Coherence Tomography (OCT) to provide real-time, high resolution, cross sectional imaging of tissue microstructures. Niris is a tool to aid in the diagnosis of a variety of diseases, early detection of abnormalities, guidance of biopsy and surgery, and post-treatment surveillance in a multitude of clinical applications.
SOURCE Imalux Corporation